|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||51.85 - 51.85|
|52 Week Range||34.14 - 54.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Valeant Pharmaceuticals International Inc said it would sell its iNova Pharmaceuticals business for $930 million, as Chief Executive Officer Joseph Papa steps up efforts to slash the embattled Canadian drugmaker's huge debt pile. The company's U.S.-listed shares were up about 3.5 percent at $12.60 in premarket trading on Thursday.
Canadian drugmaker Valeant Pharmaceuticals International Inc is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG, Bloomberg reported. Valeant's eye-surgery assets may be valued at about $2 billion in a sale, Bloomberg reported, citing people familiar with the matter. "We don't comment on speculation or rumors," Valeant spokeswoman Lainie Keller said in an email.